The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...

Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker ...

Lupus affects different people in different ways, and skin problems like rashes or sores re common. In a new study, people ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of ...

Lupus doesn’t have one clear origin. Researchers believe it comes from a complex equation of factors. One part of the equation is your genetic makeup. Another part involves the hormones that regulate ...

The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy.

The Lupus Foundation of America is dedicated to improving the quality of life for all people affected by lupus through programs of research, education, and advocacy.

In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus ...

In the Pennsylvania Delaware Valley Region, a significant number of individuals are impacted by lupus. Whether you're a lupus warrior or supporting someone who is, we're here for you. This collection ...

Drug-induced lupus is more common in men because they are given these drugs more often; however, not everyone who takes these drugs will develop the disease. Specific criteria for diagnosing ...